-
EP3679067
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3679067
| EP3679067 - CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 10.09.2021 Database last updated on 03.09.2024 | |
| Former | Request for examination was made Status updated on 12.06.2020 | ||
| Former | The international publication has been made Status updated on 16.03.2019 | ||
| Former | unknown Status updated on 17.10.2018 | Most recent event Tooltip | 15.12.2023 | Change - applicant | published on 17.01.2024 [2024/03] | Applicant(s) | For all designated states Takeda Pharmaceutical Company Limited 1-1, Doshomachi 4-chome Chuo-ku Osaka- shi, Osaka 541-0045 / JP | [2024/03] |
| Former [2020/29] | For all designated states Maverick Therapeutics, Inc. 3260 B Bayshore Blvd. 1st Floor Brisbane, CA 94005 / US | Inventor(s) | 01 /
MAY, Chad 1060 Continental Way Apt. 303 Belmont, CA 94002 / US | 02 /
DUBRIDGE, Robert, B. 825 Holly Road Belmont, CA 94002 / US | 03 /
VINOGRADOVA, Maia 2079 Ascot Drive Unit 240 Moraga, CA 94556 / US | 04 /
PANCHAL, Anand 2615 Turk Street Apt A. San Francisco, CA 94118 / US | [2020/29] | Representative(s) | HGF HGF Limited 1 City Walk Leeds LS11 9DX / GB | [N/P] |
| Former [2020/29] | HGF 1 City Walk Leeds LS11 9DX / GB | Application number, filing date | 18782832.2 | 06.09.2018 | [2020/29] | WO2018US49774 | Priority number, date | US201762555943P | 08.09.2017 Original published format: US 201762555943 P | US201762586627P | 15.11.2017 Original published format: US 201762586627 P | US201762587318P | 16.11.2017 Original published format: US 201762587318 P | [2020/29] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2019051102 | Date: | 14.03.2019 | Language: | EN | [2019/11] | Type: | A2 Application without search report | No.: | EP3679067 | Date: | 15.07.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.03.2019 takes the place of the publication of the European patent application. | [2020/29] | Search report(s) | International search report - published on: | EP | 23.05.2019 | (Supplementary) European search report - dispatched on: | EP | 13.09.2021 | Classification | IPC: | C07K16/18, C07K16/28, C07K16/30, A61P35/00 | [2020/29] | CPC: |
A61P35/00 (EP,IL,KR,US);
A61K39/00 (IL);
C07K16/30 (EP,IL,KR,US);
A61K39/39558 (IL,US);
C07K16/18 (EP,IL,KR,US);
C07K16/28 (EP,IL,KR,US);
C07K16/2809 (EP,IL,KR,US);
C07K16/2827 (EP,IL,KR,US);
C07K16/2863 (EP,IL,KR,US);
C07K16/468 (EP,IL,KR,US);
A61K2039/505 (EP,IL,KR,US);
C07K2317/31 (EP,IL,KR,US);
C07K2317/565 (IL,US);
C07K2317/569 (EP,IL,KR,US);
C07K2317/62 (EP,IL,KR,US);
C07K2317/622 (EP,IL,KR,US);
C07K2317/94 (EP,IL,KR,US);
C07K2319/00 (EP,IL,KR,US);
C07K2319/50 (EP,IL,KR,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/29] | Title | German: | EINGESCHRÄNKTE BEDINGT AKTIVIERTE BINDUNGSPROTEINE | [2020/29] | English: | CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS | [2020/29] | French: | PROTÉINES DE LIAISON À ACTIVATION CONDITIONNELLE RESTREINTE | [2020/29] | Entry into regional phase | 08.04.2020 | National basic fee paid | 08.04.2020 | Designation fee(s) paid | 08.04.2020 | Examination fee paid | Examination procedure | 08.04.2020 | Examination requested [2020/29] | 08.04.2020 | Date on which the examining division has become responsible | 03.11.2020 | Amendment by applicant (claims and/or description) | 13.09.2021 | Despatch of a communication from the examining division to which search results under Rule 164(2) EPC are annexed (Time limit: M06) [2021/41] | 13.09.2021 | Despatch of a communication from the examining division (Time limit: M06) | 22.03.2022 | Reply to a communication from the examining division | Fees paid | Renewal fee | 08.04.2020 | Renewal fee patent year 03 | 21.09.2021 | Renewal fee patent year 04 | 21.09.2022 | Renewal fee patent year 05 | 20.09.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2007042289 (ABLYNX NV [BE], et al); | [I]WO2010081173 (CYTOMX THERAPEUTICS LLC [US], et al); | [I]WO2011033105 (MICROMET AG [DE], et al); | [A]WO2011144749 (ABLYNX NV [BE], et al); | [I]WO2013083809 (AMGEN RES MUNICH GMBH [DE]); | [I]WO2016046778 (AMGEN INC [US]); | [A]WO2016156570 (ABLYNX NV [BE]); | [I]WO2016179285 (CYTOMX THERAPEUTICS INC [US]); | [A]WO2016180969 (ABLYNX NV [BE]); | [XP]WO2017156178 (MAVERICK THERAPEUTICS INC [US]); | by applicant | WO2013024059 | WO2017156178 | US2018134789 |